Beijing Kawin Bio-Tech

Beijing Kawin Technology is a leading Chinese biopharmaceutical company dedicated to the research, development, and commercialization of innovative treatments for viral diseases, particularly chronic Hepatitis C (HCV) and Hepatitis B (HBV). The company achieved a significant milestone by launching the first domestically developed all-oral, pan-genotypic HCV treatment regimen in China, centered around its core product Kebitai (Ravidasvir). Beyond its HCV portfolio, Kawin markets recombinant human interferon α2b (Kewei) and various antiviral small molecules like Kobifovir (Tenofovir Alafenamide). Listed on the Shanghai Stock Exchange's STAR Market since 2021, the company operates a fully integrated platform encompassing drug discovery, clinical development, and large-scale GMP manufacturing. Kawin continues to expand its pipeline with next-generation biologics and small molecules aimed at achieving a functional cure for HBV.